Clinical Trial Search

Primary: Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score — -9.844; -8.417 score on a scale — p=0.274

Primary: Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View. — 5.3; 4.7 millimeters

Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)

Primary: Worst Pain — 5.96; 5.74; 3.91; 4.08 score — p=0.660

Primary: Pain Severity — 8.50; 8.31 score on a scale

Primary: Foot and Ankle Ability Measure (FAAM) — 47.00; 45.28; 11.65; 11.72 Percentage of function

Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001

Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)

Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…

Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants

Primary: Visual Analog Scale Score - General Heel Tenderness — 46.7; 47.5 score on a scale

Primary: Foot and Ankle Ability Measure (FAAM) — 66.2; 72.4; 69.9; 69.3 percentage of total score

Primary: Responders Rate at Week 6 (Pain While Moving) — 25.0; 5.0 Percentage of participants — p==0.182

Primary: Change From Baseline at Week 8 in the Numeric Pain Rating Scale (NPRS) Score — -3.29; -3.25; -2.75 score on a scale

Primary: NPRS-11 — 3.8; 4.3; 3.7; 3.1 score on a scale

Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints

Primary: Average Percentage of Change as Reported Using Foot Function Index Pain Subscale — -54; -25 percentage of Change

Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001

Primary: Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12 — 64.3; 72.5 percentage of flare-ups

Primary: Static 2-point Discrimination Test — 7.3 mm

Primary: Patient Reported Pain Via the Universal Visual Analog Scale: Pass Criteria = at Least 25% Pain Reduction — 86 Percent of Patients meeting criteria

Primary: Change in Metatarsal Phalangeal Joint Angle (Degrees) in People With Diabetes From Baseline and at a 3-year Period — 0.8; -0.1 degrees

Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63

Primary: Change From Baseline at Week 8 in the Visual Analog Scale (VAS) for Pain for the Foot — -41.6; -39.3 score on a scale

Primary: Percentage of Responders at Week 6 — 100; 88.9; 88.9 percentage of subjects — p=0.1664

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Health-related Quality of Life (HRQL) Using the Michigan Hand Outcomes Questionnaire (MHQ) — 78.1; 68.3 units on a scale — p=0.05

Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants